Xiaoxiao Qian1, Palak Shah2,3, Sean Agbor-Enoh3,4,5. 1. Cardiovascular Medicine. 2. Heart Failure, MCS and Transplant, Inova Heart and Vascular Institute, Falls Church, Virginia. 3. Genomic Research Alliance for Transplantation (GRAfT). 4. Laboratory of Applied Precision Omics, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda. 5. Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Endomyocardial biopsy (EMB), the current gold standard for cardiac allograft monitoring is invasive, may have a low sensitivity and is associated with significant variability in histopathologic interpretation. Fortunately, on-going research is identifying noninvasive biomarkers that address some of these limitations. This review provides an update on noninvasive blood-based methods for rejection surveillance and diagnosis in heart transplantation. RECENT FINDINGS: Recent studies highlight good test performance to detect acute rejection for donor-derived cell-free DNA (dd-cfDNA) and microRNAs (miR). dd-cfDNA is sensitive, nonspecific, and has a high negative predictive value for acute cellular and antibody-mediated rejection. Clinical utility trials are being planned to test its role as a rule-out test for acute rejection as compared to the EMB. miRs may have an added advantage as it may phenotype the subtypes of rejection alleviating the need for an EMB or permitting the initiation of targeted therapy while awaiting the results of the EMB. SUMMARY: In this review, we discuss recent advances in the field of noninvasive biomarkers to detect allograft rejection after heart transplant. We provide a perspective of additional studies needed to prove their clinical utility and bring these biomarkers to widescale clinical use.
PURPOSE OF REVIEW: Endomyocardial biopsy (EMB), the current gold standard for cardiac allograft monitoring is invasive, may have a low sensitivity and is associated with significant variability in histopathologic interpretation. Fortunately, on-going research is identifying noninvasive biomarkers that address some of these limitations. This review provides an update on noninvasive blood-based methods for rejection surveillance and diagnosis in heart transplantation. RECENT FINDINGS: Recent studies highlight good test performance to detect acute rejection for donor-derived cell-free DNA (dd-cfDNA) and microRNAs (miR). dd-cfDNA is sensitive, nonspecific, and has a high negative predictive value for acute cellular and antibody-mediated rejection. Clinical utility trials are being planned to test its role as a rule-out test for acute rejection as compared to the EMB. miRs may have an added advantage as it may phenotype the subtypes of rejection alleviating the need for an EMB or permitting the initiation of targeted therapy while awaiting the results of the EMB. SUMMARY: In this review, we discuss recent advances in the field of noninvasive biomarkers to detect allograft rejection after heart transplant. We provide a perspective of additional studies needed to prove their clinical utility and bring these biomarkers to widescale clinical use.
Authors: Hada Celicia Macher; Noelia García-Fernández; Alejandro Adsuar-Gómez; Manuel Porras-López; Antonio González-Calle; José Noval-Padillo; Juan Miguel Guerrero; Patrocinio Molinero; José Miguel Borrego-Domínguez; Ángel Herruzo-Avilés; Amalia Rubio Journal: Clin Chim Acta Date: 2019-06-06 Impact factor: 3.786
Authors: Michael X Pham; Jeffrey J Teuteberg; Abdallah G Kfoury; Randall C Starling; Mario C Deng; Thomas P Cappola; Andrew Kao; Allen S Anderson; William G Cotts; Gregory A Ewald; David A Baran; Roberta C Bogaev; Barbara Elashoff; Helen Baron; James Yee; Hannah A Valantine Journal: N Engl J Med Date: 2010-04-22 Impact factor: 91.245
Authors: Maria G Crespo-Leiro; Jörg Stypmann; Uwe Schulz; Andreas Zuckermann; Paul Mohacsi; Christoph Bara; Heather Ross; Jayan Parameshwar; Michal Zakliczyński; Roberto Fiocchi; Daniel Hoefer; Monica Colvin; Mario C Deng; Pascal Leprince; Barbara Elashoff; James P Yee; Johan Vanhaecke Journal: Eur Heart J Date: 2016-01-07 Impact factor: 29.983